-
Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5.
AIDS. 1996 Jun;10(6):587-93
PMID: 8780812
-
Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains.
J Virol. 1999 Jul;73(7):5707-13
PMID: 10364321
-
Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.
Int Immunol. 1997 Sep;9(9):1281-90
PMID: 9310831
-
Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity.
J Immunol. 1997 Nov 15;159(10):5114-22
PMID: 9366441
-
Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries.
AIDS Res Hum Retroviruses. 1997 Dec 10;13(18):1549-59
PMID: 9430247
-
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
Nature. 1998 Jun 18;393(6686):648-59
PMID: 9641677
-
The antigenic structure of the HIV gp120 envelope glycoprotein.
Nature. 1998 Jun 18;393(6686):705-11
PMID: 9641684
-
Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.
J Virol. 1998 Sep;72(9):7099-107
PMID: 9696803
-
Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.
Cell. 1988 Jul 1;54(1):57-63
PMID: 2838179
-
Human immunodeficiency viruses: neutralization and receptors.
J Acquir Immune Defic Syndr. 1988;1(6):536-41
PMID: 2465401
-
Generation of human monoclonal antibodies to human immunodeficiency virus.
Proc Natl Acad Sci U S A. 1989 Mar;86(5):1624-8
PMID: 2922401
-
The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope.
J Virol. 1990 Jul;64(7):3240-8
PMID: 2352323
-
Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.
Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3238-42
PMID: 2014246
-
An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.
J Immunol. 1991 Jun 15;146(12):4325-32
PMID: 1710248
-
Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.
J Virol. 1991 Sep;65(9):4832-8
PMID: 1714520
-
Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: an international collaboration. Collaborating Investigators.
AIDS. 1991 Sep;5(9):1061-70
PMID: 1718320
-
A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.
Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10134-7
PMID: 1719545
-
Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity.
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10164-8
PMID: 1279672
-
Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120.
J Acquir Immune Defic Syndr. 1993 Jan;6(1):7-14
PMID: 8417177
-
Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.
J Immunol. 1993 Jan 15;150(2):635-43
PMID: 7678279
-
Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.
J Virol. 1993 Jul;67(7):3978-88
PMID: 7685405
-
Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways.
J Virol. 1993 Dec;67(12):7493-500
PMID: 7693973
-
Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change.
J Virol. 1994 Feb;68(2):674-80
PMID: 7507184
-
Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
J Virol. 1994 Aug;68(8):4821-8
PMID: 7518527
-
Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.
AIDS Res Hum Retroviruses. 1994 Apr;10(4):359-69
PMID: 7520721
-
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D.
J Virol. 1994 Nov;68(11):6994-7000
PMID: 7933081
-
Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120.
Mol Immunol. 1994 Oct;31(15):1149-60
PMID: 7935503
-
A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.
J Virol. 1995 Jan;69(1):122-30
PMID: 7527082
-
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
J Virol. 1995 Sep;69(9):5723-33
PMID: 7543586
-
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
J Virol. 1996 Feb;70(2):1100-8
PMID: 8551569
-
Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection.
J Virol. 1996 Aug;70(8):5306-11
PMID: 8764041
-
An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.
J Virol. 1998 Oct;72(10):7840-5
PMID: 9733820
-
Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.
J Virol. 1999 Jun;73(6):5225-30
PMID: 10233993
-
Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.
J Virol. 1996 Dec;70(12):8431-7
PMID: 8970964